EGFRvIII peptide (PEPvIII) (TFA)

EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy[1].

Product Specifications

UNSPSC

12352209

Target

EGFR

Type

Peptides

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfrviii-peptide-pepviii-tfa.html

Purity

98.73

Solubility

H2O : 35.4 mg/mL (ultrasonic; warming)

Smiles

O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CNC=N2)C(N[C@@H](CS)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N.OC(C(F)(F)F)=O

Molecular Formula

C72H112F3N19O26S

Molecular Weight

1748.83

References & Citations

[1]Schmittling RJ, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339 (1) :74-81.